Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

MJFF awards Nine Square Therapeutics $4.5m for Parkinson’s disease research

The research grant will help to identify drug candidates for the treatment of the disease

- PMLiVE

Publicis Groupe UK promotes Victoria Wright to CEO of Publicis Health UK

Wright first joined the group in 2007 as general manager of Publicis Resolute

- PMLiVE

Reimagining medical communications

By Jeremy Williams

- PMLiVE

Medical communications: connecting the dots from data to change

By Cathy Chow

- PMLiVE

The importance of accelerating clinical trial diversity

Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour

- PMLiVE

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Avalere Health

Top 10 Most Important Advisor Questions: Strengths and Weaknesses of Your Product

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

Impetus Digital

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

Alnylam’s patisiran backed by FDA advisory committee for ATTR cardiomyopathy

Treatment options for the underdiagnosed and rapidly progressive condition are currently limited

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links